Research and Development concerning both Bacterial and Viral Infections

The contract seeks research and development services focused on enhancing the detection and analysis of bacterial and viral infections, particularly biothreat agents, arboviruses, and antibiotic-resistant organisms, to support the NAMRU INDO PACIFIC biosurveillance program. Efforts include refining standardized laboratory procedures for testing contrived, environmental, zoonotic, and patient samples; generating detailed consensus genomes for a broader range of regional pathogens; and establishing a bioinformatic platform capable of identifying emerging and re-emerging infectious diseases using Next Generation Sequencing. All work must be performed within the United States, with wet-lab activities conducted at U.S.-based collaborative sites and dry-lab bioinformatics analyses carried out remotely or on-site in the U.S., while international fieldwork in Asia and Oceania requires prior coordination and compliance with local regulatory frameworks. The contractor is required to obtain and maintain full regulatory approvals including IRB, HRPP, and CLAR, with zero tolerance for delays or non-compliance. Deliverables encompass quarterly sequencing reports, Fasta files, trip reports, and both mid-year and final technical reports, all submitted in English within strict deadlines, particularly reporting within five days of due dates. Data, software, and results are U.S. Government property with unlimited rights, and all electronic records must be stored securely with no public disclosure without prior approval from the NAMRU INDO PACIFIC Public Affairs Office. The solicitation, issued under N0018926BUMED by the Naval Supply Systems Command Fleet Logistics Center in Norfolk, Virginia, is a sources-sought notice with no set-asides and a response deadline of May 19, 2026. Proposals must be submitted via email to the primary point of contact in Microsoft Word format and must include a cover letter with the company’s Unique Entity ID and CAGE Code, along with a capabilities statement affirming responsibility under FAR 9.104-1 and active SAM.gov registration. Compliance with Good Clinical Practices, DoD Directive 3216.02, and 32 CFR Part 219 is mandatory, and all personnel must complete CITI and research integrity training with certificates available upon request. Travel to international field sites requires a minimum two-month advance notice for ethical and protocol approvals. While no pricing data or contract value is provided due to the nature of this RFI, the evaluation basis is likely lowest price technically acceptable, with strict, binary compliance criteria governing acceptance, including completion of NGS on 90